Baird Initiates Coverage On Contineum Therapeutics with Outperform Rating, Announces Price Target of $32
Portfolio Pulse from Benzinga Newsdesk
Baird has initiated coverage on Contineum Therapeutics with an Outperform rating and set a price target of $32.
October 22, 2024 | 9:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird has initiated coverage on Contineum Therapeutics with an Outperform rating and a price target of $32, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $32 by a reputable analyst can lead to increased investor interest and potential buying activity, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100